Strategic partnerships SAB BIO is actively engaging with large collaborators like Emergent BioSolutions to support process development and manufacturing of SAB-142, signaling a open to collaborative scale-up opportunities that can be paired with contract development and manufacturing organizations (CDMO) offerings.

Clinical momentum The company is in clinical-stage development for fully human anti-thymocyte immunoglobulin (hATG) targeting type 1 diabetes, with frequent conference presence and upcoming ADA Scientific Sessions, presenting opportunities to connect with investigators, trial sites, and sponsor groups seeking novel autoimmune therapies.

Financial runway With a recent $85 million public offering and total funding around $175 million alongside revenue in the tens of millions, SAB BIO exhibits growing financial capacity to invest in additional trials, manufacturing scale, and strategic partnerships, making it a viable collaborator for funding-aligned ventures.

Immunology focus Specialization in fully human ATG for autoimmune diseases positions SAB BIO to explore cross-therapeutic partnerships in T1D and related autoimmune indications, including potential interest from CROs, biotechs, and pharma players seeking immunotherapy platforms.

Tech and logistics fit Adoption of established tech like Veeva and CDMO-friendly processes, plus a multiple-vendor manufacturing pathway via Emergent, indicates readiness for vendor-managed collaboration, data integration, and accelerated onboarding of additional suppliers, investigators, or manufacturing partners.